FLORHAM PARK, NJ, Jan. 04, 2023 (GLOBE NEWSWIRE) — Celularity Inc. CELU (“Celularity”), a biotechnology company developing placenta-derived allogeneic cell and biomaterial therapies, today announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2, 2023. Mr. Graves is a seasoned communications professional bringing more than 30 years of strategic communications experience in the biopharmaceutical industry. He has deep expertise in corporate reputation, global research and development, product launch and promotion, investor relations and public affairs. He will lead Celularity’s strategic communications as the company advances its broad clinical pipeline toward U.S. Food and Drug Administration (FDA) filings and approvals.

“We are very pleased to welcome Paul to Celularity at this exciting moment in our career,” said Robert J. Hariri, MD, Ph.D., Celularity’s founder, chairman and chief executive officer. “We are developing important clinical-stage products leveraging our unique placenta-derived allogeneic platform. Paul will play a critical role in helping us communicate the potential of these products as they continue to meet important milestones and highlight the industry’s leadership from Cellularity and the deep commitment of our people.”

“Celularity is making rapid progress, with multiple assets in clinical development and a number of commercially available biomaterial products that have the potential to positively impact physicians and patients in new and unprecedented ways,” said Mr. Graves. “I am excited to join Celularity as part of the leadership team to promote awareness of our unique history and highlight our continued progress. It is a privilege to raise awareness of the company’s vision of using the unique biology and availability of the human placenta to improve the lives of patients and tell the scientists’ stories of…